$12.580
+0.081 (+0.64%)收盘时
ATXS 资讯
ATXS 事件
BioCryst Completes Acquisition of Astria for Approximately $700 Million
BioCryst Pharmaceuticals (BCRX) announced that it has completed its acquisition of Astria Therapeutics (ATXS) initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema, HAE, and enhances the company's long-term growth trajectory. The acquisition was completed for an implied transaction value of approximately $700 million, net of Astria's cash at closing. BioCryst financed the cash portion of the acquisition with cash on hand and approximately $396.6 million drawn from a financing facility with funds managed by Blackstone. In addition, at the closing of the transaction, BioCryst issued approximately 37.3 million shares of its common stock to Astria's equity holders.
Astria Therapeutics Approved Acquisition by BioCryst Pharmaceuticals
Astria Therapeutics, Inc. (ATXS) announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals (BCRX). The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions.
BioCryst Receives Early Termination for Acquisition of Astria
BioCryst Pharmaceuticals (BCRX) has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended with respect to BioCryst's proposed acquisition of Astria Therapeutics (ATXS). Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst expects the Merger to close in the first quarter of 2026, subject to other customary closing conditions.
Astria Therapeutics reveals conclusive findings from the ALPHA-STAR trial
Astria Therapeutics announced results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema patients. Conducted across 20 sites in six countries, the trial demonstrated robust attack rate reduction, along with a favorable safety and tolerability profile, supporting both every three-month and every six-month dosing regimens. These results reinforce the potential of navenibart's profile to provide effective, long-acting prevention from HAE attacks and highlight Astria's strong global clinical execution as the Phase 3 program progresses, with topline results expected in early 2027. Through six months of treatment, expanded Cohorts 2 and 3 had a 62% and 67% attack-free rate, respectively, consistent with previously reported results. Clinically meaningful improvements in patient-reported quality of life were demonstrated at 6 months. Navenibart was generally well-tolerated with no serious treatment-emergent adverse events, no discontinuations, and no injection site reactions of pain. There were four non-severe and quickly resolved treatment-related TEAEs: one case of dizziness, a transient injection site reaction, an injection site erythema, and an injection site pruritus. All 29 patients in the ALPHA-STAR trial elected to enroll in the ALPHA-SOLAR long-term open-label trial and continue receiving navenibart.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。